Evolving treatment options for patients with AML ineligible for intensive chemotherapy
2024-10-29 16:00 - 18:00 (Europe/Paris)
Find more info in this flyer.
Location: Aarhus University Hospital AUH SYD, auditorium C114-101. Indgang C, C110 or join online.

Please send your registration for the meeting before October 16th to Daniel Tuyet Kristensen (dankrt@rm.dk). Please note if you will participate in person or online to receive a link.

mIDH1-mutated AML: ivosidenib in clinical practice
2024-11-21 00:00 - 13:00 (Europe/Paris)
This Servier arranged webinar is for hematologists. The agenda for the webinar is:
12:00-12:05 – Introduction by Erik Holgén, Product Manager, Servier
12:05-12:30 – Prof. Dr. Michael Heuser – Will present the AGILE study and the clinical implications of the study results.
12:30-12:45 – Docent Vladimir Lazarevic – Focusing on treatment of mIDH1 AML patients in the future
12:45-13:00 – Questions & Answers
——————-
Unable to attend at this time? Register anyway to receive the recording afterwards.
Click here to register

MNSCT 2024 Meeting
2024-11-21 12:00 - 17:00 (Europe/Paris)
MNSCT 2024 Meeting
Date: 21 November 2024
Venue: Grand Hotel, Lund, Sweden or online
Registration: https://mkon.nu/mnsct_2024/registration
Program
12:00-12:55 Lunch, registration starts at 11.45
13:00-13:05 Welcome/Introduction (Assoc. Prof. Andreas Björklund, Stockholm, Assoc. Prof. Jörg Cammenga, Lund)
Session 1:
13:05-13:45 Prof. Dr. Thomas Schröder, University Hospital Essen, Essen Germany — “Pharmacological preemptive and prophylactic approaches to prevent/treat relapse of myeloid neoplasms after allo SCT”
13:40-14:20 Assoc. Professor Dr. Luca Vago, Milan, Italy — “Mechanisms of immune escape after allogeneic stem cell transplantation”
14:20-14:30 Coffee break
Session 2:
14:30-15:10 Ass. Professor Dr. A, Mishra, MD (Tampa, Florida) — “Targeted agents post- allo HSCT based on mutational status”
15:15-15:55 Ass. Professor Dr. Jacqueline S. Garcia, MD (Harvard Medical School, Dana-Farber Cancer Institute) — “Post transplant maintenance: Finding the sweet spot”
16:00-16:55 Plenary discussion (all speakers (virtual/local) + moderators)
16:55-17:00 Closing remarks

NAMLG Breakfast Meeting @ ASH
2024-12-07 07:00 - 09:00 (America/Los_Angeles) | 675 L St, San Diego, CA 92101, USA, 675 L Street, San Diego, CA, 92101, United States
You are cordially invited to the NAMLG Breakfast Meeting, held during ASH in San Diego.
Date: Saturday, December 7th
Time: 7:00 AM – 9:00 AM
This event is generously sponsored by AbbVie.
To register, please contact Bjørn Tore Gjertsen (Bjorn.Gjertsen@uib.no).

NAMLG Lunch Meeting in Munich
2025-03-17 12:00 - 14:00 (Europe/Paris)
For Nordic AML physicians attending the Acute Leukemia Symposium ISALXIX in Munich 16-19th March 2025, You are cordially invited to a NAMLG Lunch Meeting in
on Monday March 17th, 12.00-14.00. Find more info in this flyer. [With support from Servier and the organizing committee in Munich.]

The c-myc Single Cell Satellite Seminar
2025-05-12
The newly established Jebsen Centre for Myeloid Blood Cancer (c-myc) will have their first Annual c-myc Seminar as a full-day satellite to CCBIO’s 13th Annual Symposium and will showcase recent advancements in single-cell genomics, transcriptomics, proteomics, and preclinical trials, setting the stage for future clinical applications. The event will bring together leading researchers to explore how single-cell resolution can advance cancer treatment and improve patient outcomes. For program, registration and practical information, please consult the seminar website.

The 13th CCBIO Annual Symposium
2025-05-13 - 2025-05-14
CCBIO has the pleasure of inviting you to the 13th CCBIO Annual Symposium May 13-14, and now, PREFINAL PROGRAM is available.
To participate, please register within April 1.
There will be a strong scientific program including a range of international speakers, among them Sir David Lane, Eva Hellström-Lindberg, Theodoros Foukakis, Anna Dimberg, Steinar Ø. Thoresen, Gema Moreno-Bueno and Jean Albrengues.

AML Course Day 10 September 2025
2025-09-10
The Educational Working Group is planning an “AML Course Day” in conjunction with the Nordic AML Meeting in Bergen 2025.
The AML Course Day covers topics such as the current diagnostics and therapeutics, the latest with regard to MRD as well as clinically inclined discussions on emergencies and infectious problems in AML.
The AML Course Day will be open for registration for physicians in the Nordics who take care of patients with AML.
More information is coming, but save-the-date!

Presentation of a Nordic platform for future collaborative projects on TP53 mutated myeloid malignancies
2025-09-10 20:00 - 21:30 (Europe/Paris)
It’s an open meeting for clinicians and preclinical researchers but meant for those that are actually interested to take part in future Nordic collaborative TP53 related myeloid research.
The meeting will be held at Hotel Norge, Bergen, in connection with the NAMLG meeting, Room number will be announced at the hotel reception.
The meeting will also be possible to attend by Zoom.
Chair: Professor Sören Lehmann, Sweden

Nordic AML Meeting 11-12 September 2025
2025-09-11 - 2025-09-12
Save the dates for the upcoming Nordic AML Meeting in Bergen, Norway, 2025.

Personalized Medicine in the Treatment of AML
2025-12-17 15:00 - 17:00 (Europe/Paris)
Jazz Pharmaceuticals is pleased to invite hematologists from the Nordic AML Group to join a distinguished academic webinar featuring Prof. Dr. med. Lars Bullinger and Prof. Bjørn Tore Gjertsen, two leading experts in hematology and leukemia research.
Find more info using this link.
Register using this QR code

NAMLG - Steering group meeting
2026-01-13 16:00 - 17:00 (Europe/Paris)
Agenda and meeting link will be sent via e-mail.

Best of ASH 2025 by Lund
2026-01-20 15:00 - 19:00 (Europe/Paris)
At Best of ASH 2025, hematologists in Lund, Sweden present their top picks from the annual meeting of the American Society of Hematology (ASH) cutting through the volume to focus on data that change how we treat patients. Expect concise, expert-led updates on key trials, late-breaking abstracts, and their real-world implications across hematology.
Live on YouTube: https://www.youtube.com/live/DJrW-8hEHvI

Webinar - Innovations in AML care: Integrating Novel Treatments into Nordic Practice
2026-02-26 14:00 - 15:15 (Europe/Paris) | https://www.namlg.org/event/webinar-innovations-in-aml-care/
The Nordic AML Group’s Educational Working Group invites you to a scientific webinar focusing on recent innovations in the treatment of AML and their implementation in Nordic clinical practice.
The webinar will feature three expert speakers covering:
– The evolving AML treatment landscape by professor Gail Roboz (New York)
– Early Nordic experience with new AML therapies and ongoing Nordic studies by professor Bjørn Tore Gjertsen (Bergen)
– Access pathways and future developments in AML care by associate professor Anne Louise Tølbøll Sørensen (Copenhagen)
Aim: To provide a clinically relevant and up-to-date overview of emerging therapeutic approaches for AML, with particular emphasis on feasibility, relevance, and early adoption within the Nordic region.
Format: Webinar via Zoom via this link
Sponsorship: Sponsored by Otsuka. The sponsor has no influence on the scientific content or agenda.
#################################
Agenda – 2026-02-26 – 14:00 – 15:15 (CET)
14:00 – 14:05 – Welcome & Introduction
14:05 – 14:20 – The Evolving AML Landscape, Professor Gail Roboz (New York)
14:20 – 14:35 – From Data to Practice: Early Nordic Experience with New AML Treatments, Professor Bjørn Tore Gjertsen (Bergen)
14:35 – 14:45 – Discussion
14:45 – 15:00 – Ongoing Nordic Studies, Access Pathways, and What’s Coming Next, Associate professor Anne Louise Tølbøll Sørensen (Copenhagen)
15:00 – 15:10 – Discussion
15:10 – 15:15 – Closing remarks
#################################

NAMLG – Steering group meeting
2026-03-03 16:00 - 17:00 (Europe/Paris)

Germline Predisposition to Myeloid Neoplasms - Case discussions
2026-03-05 15:00 - 16:00 (Europe/Paris)
Join the MDR for patients with germline predisposition for hematological malignancies.
This meeting is for clinicians within the Nordics via this Zoom-link.
If you want to discuss a case, please send 1-2 summary slides with the most important information to Panagiotis Baliakas (panagiotis.baliakas@igp.uu.se), Uppsala, Sweden.

Webinar - Ask the expert: FLT3 MRD testing in AML patients
2026-03-17 17:00 - 18:00 (Europe/Paris)
Take the chance to join an Astellas Pharma sponsored webinar with Dr. Mark J. Levis, MD, PhD, Baltimore, USA, entitled Ask the expert: FLT3 MRD testing in AML patients via Teams with the following agenda:
Assess the current minimal residual disease testing modalities/methods
 Evaluate appropriate timing and efficacy of different FLT3 MRD testing modalities
 Summarize the appropriate treatment strategies in a post-transplant setting
 Best practice sharing in developing/setting up FLT3 MRD testing
More info and register here.

Germline Predisposition to Myeloid Neoplasms – Case discussions
2026-05-07 15:00 - 16:00 (Europe/Paris)
Join the MDR for patients with germline predisposition for hematological malignancies.
This meeting is for clinicians within the Nordics.via this Zoom-link.
If you want to discuss a case, please send 1-2 summary slides with the most important information to Panagiotis Baliakas (panagiotis.baliakas@igp.uu.se), Uppsala, Sweden.

NAMLG meeting @ EHA2026
2026-06-13 00:30 - 14:00 (Europe/Paris)

AML Course Day 2026 - Bergen
2026-09-16 08:00 - 17:00 (Europe/Paris)

Nordic AML Meeting 2026 - Bergen
2026-09-17 - 2026-09-18
